electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$4.84 – $5.41
Volume97,352
Market cap$45M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$44.65M
Price / earnings
—
Price / book
-17.8×
Price / sales
1.18×
EV / sales
1.19×
EV / EBITDA
-3.64×
Profitability
Earnings per share
-$1.38
Return on assets
-73.61%
Return on equity
506.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-2.75×
Current ratio
1.34×
Quick ratio
0.97×
Cash ratio
0.58×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$10.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ECOR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$9.69M
$9.45M
$9.58M
$9.24M
$8.69M
$7.38M
$6.72M
$7.05M
Cost of revenue
$1.12M
$1.27M
$1.22M
$1.07M
$1.22M
$939K
$1.01M
$994K
Gross profit
$8.57M
$8.18M
$8.36M
$8.17M
$7.47M
$6.44M
$5.71M
$6.05M
Selling, general and administrative
$9.7M
$10.13M
$12.94M
$10.19M
$9.69M
$9.44M
$8.89M
$8.32M
Research and development
$431K
$818K
$740K
$920K
$662K
$511K
$642K
$805K
Total operating expenses
$10.13M
$10.95M
$13.68M
$11.11M
$10.35M
$9.95M
$9.53M
$9.12M
Operating income
-$1.56M
-$2.77M
-$5.32M
-$2.94M
-$2.88M
-$3.51M
-$3.82M
-$3.07M
Interest expense
-$370K
-$321K
-$318K
-$324K
-$208K
-$5K
-$5K
-$261K
Income before taxes
-$1.47M
-$3.06M
-$5.59M
-$2.98M
-$3.41M
-$3.67M
-$3.9M
-$3.2M
Income taxes
-$126K
$0
-$321K
$51K
$0
$0
-$48K
$29K
Net income
-$1.34M
-$3.06M
-$5.27M
-$3.04M
-$3.41M
-$3.67M
-$3.86M
-$3.23M
Net income attributable to common shareholders
-$1.34M
-$3.06M
-$5.27M
-$3.04M
-$3.41M
-$3.67M
-$3.86M
-$3.23M
EBITDA
-$1.55M
-$2.77M
-$5.3M
-$2.83M
-$2.77M
-$3.39M
-$3.67M
-$2.9M
Basic earnings per share
-$0.13
-$0.33
-$0.59
-$0.34
-$0.40
-$0.44
-$0.47
-$0.39
Diluted earnings per share
-$0.13
-$0.33
-$0.59
-$0.34
-$0.40
-$0.44
-$0.47
-$0.39
Recent news
Company coverage with links to the original publishers.
electroCore and Sonocea published results from a randomized controlled trial evaluating non-invasive neuromodulation technologies for Long COVID treatment. The study of 250 participants showed improvements in fatigue, cognition, sleep, and mental health symptoms across active intervention groups compared to monitoring-only controls, with depressive symptoms decreasing 31-34% and PTSD symptoms reducing 39% with combined therapy. However, the open-label design without sham control and reliance on patient-reported outcomes limit the findings, which are considered hypothesis-generating and warrant confirmation in larger, sham-controlled studies.
electroCore, Inc. (ECOR) has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimate revisions over the past three months, with consensus estimates increasing 14.1%. The upgrade reflects improved business fundamentals and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation.
Neurocrine Biosciences (NBIX) reported Q3 2026 earnings of $3.29 per share, beating consensus estimates of $2.54 by 29.53%, with revenues of $1.12 billion exceeding expectations by 8.12%. However, the stock has gained only 3% year-to-date versus the S&P 500's 10.7% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
electroCore (ECOR) shares surged 6.9% to $11.38 following raised 2026 revenue-growth outlook of over 30% and improved operating performance. Q2 revenues increased 28% YoY to $9.5 million with narrowed adjusted EBITDA losses. However, the stock carries a Zacks Rank #3 (Hold) as earnings estimate revisions have remained flat over the past 30 days.
electroCore announced that its Truvaga non-invasive vagus nerve stimulation (nVNS) wellness brand has been named the 2026 Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. The recognition highlights Truvaga's combination of patented technology, thoughtful design, and personalized customer experience. The company also reported Q2 2026 net sales of $9.5 million, a 28% increase year-over-year, with net losses decreasing 17%.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.